Skip to main content
Livermore
Livermore
ZHEN

VR Adviser, LLC

SEC CIK
0001615982
Latest filing
Aug 14, 2026

The latest 13F from VR Adviser, LLC covers Q2 2026 (filed Aug 14, 2026): 33 long positions worth $3.30B. The top 10 holdings make up 80.4% of the portfolio, and the largest is Apogee Therapeutics, Inc. (APGE) at 34.2%. Livermore has 25 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
4
Est. +$38.3M
Added
5
Est. +$59.4M
Reduced
5
Est. −$167.1M
Sold out
4
Est. −$201.8M

Top 5 holdings

Share of this quarter's portfolio value

  1. APGEApogee Therapeutics, Inc.
    34.2%$1.13BHistory
  2. ORKAOruka Therapeutics, Inc.
    12.0%$394.8MHistory
  3. ERASErasca, Inc.
    9.9%$327.8MHistory
  4. SYRESpyre Therapeutics, Inc.
    8.0%$265.0MHistory
  5. DNTHDianthus Therapeutics, Inc.
    3.5%$115.0MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. ERASErasca, Inc.
    +$27.6MAddedHistory
  2. ACHVAchieve Life Sciences, Inc.
    +$18.0MNewHistory
  3. PBLSParabilis Medicines, Inc.
    +$17.1MNewHistory
  4. RLMDRelmada Therapeutics, Inc.
    +$13.8MAddedHistory
  5. XFORX4 Pharmaceuticals, Inc
    +$7.49MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. ACHVAchieve Life Sciences, Inc.
    +0.54 pp0.0% → 0.5%History
  2. PBLSParabilis Medicines, Inc.
    +0.52 pp0.0% → 0.5%History
  3. XFORX4 Pharmaceuticals, Inc
    +0.22 pp0.1% → 0.3%History
  4. ARTVArtiva Biotherapeutics, Inc.
    +0.21 pp0.4% → 0.6%History
  5. RLMDRelmada Therapeutics, Inc.
    +0.18 pp1.3% → 1.4%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. KALVKalVista Pharmaceuticals, Inc.
    −$130.3MSold outHistory
  2. SYRESpyre Therapeutics, Inc.
    −$62.1MReducedHistory
  3. ELVNEnliven Therapeutics, Inc.
    −$60.9MReducedHistory
  4. ENGNenGene Therapeutics Inc.
    −$32.5MSold outHistory
  5. TENXTenax Therapeutics, Inc.
    −$26.8MSold outHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. KALVKalVista Pharmaceuticals, Inc.
    −4.86 pp4.9% → 0.0%History
  2. ELVNEnliven Therapeutics, Inc.
    −1.72 pp2.5% → 0.8%History
  3. ENGNenGene Therapeutics Inc.
    −1.21 pp1.2% → 0.0%History
  4. CTMXCytomX Therapeutics, Inc.
    −1.18 pp1.8% → 0.6%History
  5. VRDNViridian Therapeutics, Inc.
    −1.02 pp2.8% → 1.8%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$3.30B
+$618.9M (+23.1%) vs. prior quarter
Positions
33
0 vs. prior quarter
Top 10 concentration
80.4%
Top 10 as share of value
Turnover
3.3%
Q2 2026, one quarter
Average holding period
9.8 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $3.30B (Q2 2026)

Q1 2021: $921.8MQ2 2021: $824.4MQ3 2021: $778.5MQ4 2021: $731.5MQ1 2022: $617.2MQ2 2022: $507.8MQ3 2022: $648.1MQ4 2022: $593.6MQ1 2023: $512.2MQ2 2023: $625.4MQ3 2023: $949.9MQ4 2023: $1.46BQ1 2024: $2.10BQ2 2024: $1.57BQ3 2024: $1.91BQ4 2024: $1.46BQ1 2025: $1.18BQ2 2025: $1.33BQ3 2025: $1.78BQ4 2025: $2.02BQ1 2026: $2.68BQ2 2026: $3.30B
Q1 2021Q2 2026
13F filings of VR Adviser, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 202633$3.30BAPGEORKAERASvs. Q1 2026SEC
Q1 2026May 15, 202633$2.68BAPGEERASORKAvs. Q4 2025SEC
Q4 2025Feb 17, 202627$2.02BAPGEORKAVRDNvs. Q3 2025SEC
Q3 2025Nov 14, 202533$1.78BAPGEMTSROCULvs. Q2 2025SEC
Q2 2025Aug 14, 202531$1.33BAPGEOCULMTSRvs. Q1 2025SEC
Q1 2025May 15, 202537$1.18BAPGEMTSROCULvs. Q4 2024SEC
Q4 2024Feb 14, 202537$1.46BAPGEOCULELVNvs. Q3 2024SEC
Q3 2024Nov 14, 202438$1.91BAPGEOCULELVNvs. Q2 2024SEC
Q2 2024Aug 14, 202435$1.57BAPGEELVNFDMTvs. Q1 2024SEC
Q1 2024May 15, 202438$2.10BAPGEFDMTOCULvs. Q4 2023SEC
Q4 2023Feb 14, 202436$1.46BRYZBAPGEPHVSvs. Q3 2023SEC
Q3 2023Nov 14, 202337$949.9MAPGERYZBVRDNvs. Q2 2023SEC
Q2 2023Aug 11, 202330$625.4MVRDNCOGTFDMTvs. Q1 2023SEC
Q1 2023May 15, 202325$512.2MVRDNCOGTELVNvs. Q4 2022SEC
Q4 2022May 15, 2023Amended28$593.6MVRDNACRSAXSMvs. Q3 2022SEC
Q3 2022May 15, 2023Amended31$648.1MTCDAACRSCOGTvs. Q2 2022SEC
Q2 2022May 15, 2023Amended27$507.8MTCDAACRSRLMDvs. Q1 2022SEC
Q1 2022May 16, 202227$617.2MACRSTILRLMDvs. Q4 2021SEC
Q4 2021Feb 14, 202226$731.5MTILACRSTVTXvs. Q3 2021SEC
Q3 2021Nov 15, 202126$778.5MTILACRSCLDXvs. Q2 2021SEC
Q2 2021Aug 13, 202129$824.4MTILACRSVTGNvs. Q1 2021SEC
Q1 2021May 14, 202128$921.8MTILCNSTACRS–SEC